Dual therapy with nivolumab plus ipilimumab seems to achieve higher response rates and prolong survival more than nivolumab monotherapy in metastatic melanoma patients, regardless of the BRAF status [22,23]. This evidence concerns the gene BRAF and metastatic melanoma.